Therapy Detail

Therapy Name Axitinib
Therapy Description

Inlyta (axitinib) inhibits the VEGFRs, PDGFR, and KIT, potentially resulting in decreased angiogenesis and reduced tumor growth (PMID: 16027439, PMID: 25709499). Inlyta (axitinib) is approved for renal cell carcinoma (FDA.gov).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Axitinib Inlyta AG-013736 KIT Inhibitor 48 PDGFR Inhibitor (Pan) 27 VEGFR Inhibitor (Pan) 29 Inlyta (axitinib) inhibits the VEGFRs, PDGFR, and KIT, potentially resulting in decreased angiogenesis and reduced tumor growth (PMID: 16027439, PMID: 25709499). Inlyta (axitinib) is approved for renal cell carcinoma (FDA.gov).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown neuroendocrine tumor not applicable Axitinib Phase II Actionable In a Phase II clinical trial, treatment with Inlyta (axitinib) resulted in a median overall progression-free survival (PFS) of 26.7 months, a 12-month PFS rate of 74.5%, and median overall survival of 45.3 months, and led to partial response in 3% (1/30) and stable disease in 70% (21/30) of patients with neuroendocrine tumors, with some tumor shrinkage in 68% (15/22) of patients (PMID: 27080472). 27080472
Unknown unknown breast cancer not applicable Axitinib Preclinical - Cell line xenograft Actionable In a preclinical study, Inlyta (axitinib) disrupted tumor microvasculature and inhibited tumor growth in breast cancer cell line xenograft models (PMID: 17371720). 17371720
Unknown unknown non-small cell lung carcinoma not applicable Axitinib Phase II Actionable In a Phase II clinical trial, Inlyta (axitinib) was well-tolerated and demonstrated activity in patients with advanced non-small cell lung cancer, with a disease control rate of 41% (13/32), median progression-free survival of 4.9 months, and median overall survival of 14.8 months (PMID: 19597027). 19597027
Unknown unknown brain glioblastoma multiforme not applicable Axitinib Preclinical Actionable In a preclinical study, Inlyta (axitinib) demonstrated efficacy in glioblastoma cells, including those resistant to Bevacizumab (J Clin Oncol (Meeting Abstracts) May 2013 vol. 31 no. 15_suppl 2077). detail...
Unknown unknown thyroid cancer not applicable Axitinib Phase II Actionable In a Phase II study, Inlyta (axitinib) demonstrated antitumor activity in patients with advanced refractory thyroid cancer, resulting in a 30% response rate with another 38% of patients having stable disease (PMID: 20694064). 20694064
Unknown unknown melanoma not applicable Axitinib Phase II Actionable In a Phase II study in patients with metastatic melanoma, Inlyta (axitinib) was well tolerated and demonstrated antitumor activity (PMID: 21976544). 21976544
Unknown unknown renal cell carcinoma not applicable Axitinib Clinical Study Actionable In a meta-analysis, Inlyta (axitinib) improved progression-free survival in patients with metastatic renal cell carcinoma (PMID: 24037486). 24037486
Unknown unknown renal cell carcinoma not applicable Axitinib FDA approved Actionable In a Phase III trial that supported FDA approval, treatment with Inlyta (axitinib) as second-line therapy resulted in an improved progression-free survival of 8.3 months compared to 5.7 months with Nexavar (sorafenib) (HR 0.656, 95% CI 0.552-0.779; p<0.0001) in patients with metastatic renal cell carcinoma (PMID: 23598172). 23598172
Unknown unknown renal cell carcinoma not applicable Axitinib Phase II Actionable In a Phase II clinical trial, treatment with Inlyta (axtinib) as first-line therapy resulted a prolonged median overall survival of 42.7 months compared to 30.4 months with placebo in patients with metastatic renal cell carcinoma (PMID: 27236772). 27236772
Unknown unknown nasopharynx carcinoma not applicable Axitinib Preclinical - Cell line xenograft Actionable In a preclinical study, Inlyta (axitinib) inhibited growth of nasopharyngeal carcinoma cell lines in culture, and inhibited tumor growth, decreased microvessel density, and increased tumor necrosis in a nasopharyngeal carcinoma xenograft model (PMID: 29301831). 29301831
Unknown unknown nasopharynx carcinoma not applicable Axitinib Clinical Study Actionable In a clinical trial, treatment with Inlyta (axitinib) resulted in a 3-month clinical benefit rate (CBR) of 78.4% (29/37; 1 confirmed partial response (PR), 6 unconfirmed PR, 22 stable disease for greater than 3 months) and 6-month CBR of 43.2%, a median progression-free survival of 5.0 months, and median overall survival of 10.4 months in patients with nasopharyngeal carcinoma (PMID: 29301831). 29301831
Unknown unknown Advanced Solid Tumor not applicable Axitinib Phase I Actionable In a Phase I trial, Inlyta (axitinib), in combination with chemotherapeutics, demonstrated antitumor activity in 42% (17/42) of patients with advanced solid tumors (PMID: 22996612). 22996612
Clinical Trial Phase Therapies Title Recruitment Status
NCT00828919 Phase I Axitinib Continuing Access To AG- 013736 (A406) For Patients Previously Receiving AG 013736 In Clinical Trials Active, not recruiting
NCT02693535 Phase II Vemurafenib + Cobimetinib Regorafenib Vismodegib Bosutinib Palbociclib Cetuximab Axitinib Pembrolizumab Temsirolimus Dasatinib Pertuzumab + Trastuzumab Crizotinib Sunitinib Olaparib Erlotinib TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer Recruiting
NCT03839498 Phase II Axitinib Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma Recruiting
NCT02667886 Phase Ib/II Axitinib X4P-001 Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma Active, not recruiting
NCT02164838 Phase I Axitinib VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors Completed
NCT01409200 Phase II Axitinib Neoadjuvant Axitinib in Prostate Cancer Active, not recruiting
NCT02129647 Phase II Axitinib Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Active, not recruiting
NCT01599754 Phase III Axitinib Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients Terminated
NCT02639182 Phase II AGS-16C3F Axitinib A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma Active, not recruiting
NCT01967576 Phase II Axitinib Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma Active, not recruiting
NCT03438708 Phase II Axitinib Prior Axitinib as a Determinant of Outcome of Renal Surgery (PADRES) Recruiting
NCT02551718 Phase I Bosutinib Irinotecan romidepsin Busulfan Melphalan Nilotinib Crizotinib Cytarabine Mitoxantrone Dasatinib Pazopanib Paclitaxel Clofarabine Hydroxyurea Tretinoin Carfilzomib Nelarabine Bexarotene Pentostatin Everolimus Cabozantinib Mercaptopurine Methotrexate Cladribine Thioguanine Daunorubicin Ponatinib Etoposide Afatinib Gefitinib Gemcitabine Regorafenib Arsenic trioxide Trametinib Imatinib Erlotinib Dabrafenib Decitabine Axitinib Azacitidine Ruxolitinib Fludarabine Lapatinib Ceritinib Sirolimus Sorafenib Lomustine Sunitinib Cabazitaxel Temsirolimus Topotecan Bortezomib Pralatrexate High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia Recruiting
NCT02579811 Phase II Axitinib Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer Active, not recruiting
NCT01321437 Phase II Axitinib Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma Active, not recruiting
NCT03297606 Phase II Bosutinib Palbociclib Vismodegib Nivolumab + Ipilimumab Vemurafenib + Cobimetinib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR) Recruiting
NCT01533948 Phase II Axitinib Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery Terminated
NCT02560012 Phase II Everolimus Sorafenib Temsirolimus Axitinib Sunitinib Pazopanib Personalized Targeted Inhibitors Treatment in Renal Cell Cancer Terminated
NCT01727336 Phase II Dalantercept + Axitinib Axitinib Study of Dalantercept in Patients With Advanced Renal Cell Carcinoma Completed
NCT03092856 Phase II Axitinib Axitinib + PF-04518600 Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer Recruiting
NCT02762513 Phase II Axitinib Expansion Trial for Axitinib In Head And Neck Cancer Recruiting
NCT03595124 Phase II Nivolumab Axitinib + Nivolumab Axitinib Axitinib and Nivolumab in Treating Participants With Unresectable or Metastatic TFE/Translocation Renal Cell Carcinoma Recruiting
NCT01540526 Phase I Axitinib Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib Completed
NCT01508117 Phase II Axitinib Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients Terminated
NCT01649180 Phase II Axitinib NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (PrE0801) Terminated
NCT02788201 Phase II Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifine Crizotinib Dactinomycin Temsirolimus Vorinostat romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma Recruiting